Floatz logo

TIL

Effects of Immunotherapy

Shanghai Juncell TherapeuticsCell therapyPhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Effects of Immunotherapy cohort.

Asset / SponsorPhaseRating
Recombinant Wt1 Antigen-Specific Cancer Immunotherapeutic
Jules Bordet Institute
Phase 1/2CCC
Nivolumab
Leiden University
Phase 1/2CCC
Alpha-Interferon
Leiden University
Phase 1/2CCC
Ipilimumab
Radiotherapie
Phase 1CC
Axalimogene Filolisbac
Advaxis, Inc.
Phase 1CC

View all 10 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →